BillionToOne Announces Pricing of Upsized Initial Public Offering

Rhea-AI Summary

BillionToOne (Nasdaq: BLLN) priced an upsized initial public offering of 4,551,100 shares of Class A common stock at $60.00 per share, with expected gross proceeds of approximately $273.1 million before underwriting discounts and expenses.

The underwriters have a 30-day option to purchase up to an additional 682,665 shares at the IPO price. Shares are expected to begin trading on the Nasdaq Global Select Market on November 6, 2025, and the offering is expected to close on November 7, 2025, subject to customary closing conditions.

Positive

• 4,551,100 shares priced at $60.00 per share
• Expected $273.1M gross proceeds before fees
• Listing on Nasdaq Global Select beginning Nov 6, 2025
• Underwriter syndicate includes J.P. Morgan, Piper Sandler, Jefferies, William Blair

Negative

• Existing shareholders face dilution from the 4,551,100 share offering
• Net proceeds will be reduced by underwriting discounts, commissions and offering expenses
• Underwriters' 30-day option could increase share count by 682,665

Insights

Equity Capital Markets Analyst

Upsized IPO priced at $60.00 for 4,551,100 shares, raising about $273.1 million; listing to begin Nov 6, 2025.

BillionToOne priced an upsized initial public offering of 4,551,100 Class A shares at $60.00 per share, with underwriters able to buy up to an additional 682,665 shares. The deal’s gross proceeds are about $273.1 million before fees, and the offering is expected to close on Nov 7, 2025 with trading starting on Nov 6, 2025.

This raises near‑term capital for the company and confirms market demand strong enough to upsize the deal and secure multiple book‑runners. Key dependencies include actual exercise of the 30‑day overallotment, final net proceeds after underwriting fees, and customary closing conditions; those items will determine final cash raised and dilution. Watch the closing on Nov 7, 2025, the underwriters’ exercise decision within 30 days, and initial trading liquidity on Nov 6, 2025 for signals about market reception.

MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the pricing of its upsized initial public offering of 4,551,100 shares of its Class A common stock, at a public offering price of $60.00 per share. In addition, BillionToOne has granted the underwriters a 30-day option to purchase up to an additional 682,665 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on November 6, 2025, under the ticker symbol “BLLN.” The gross proceeds from the offering are expected to be approximately $273.1 million, without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on November 7, 2025, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Piper Sandler, Jefferies and William Blair are acting as joint book-running managers for the offering. Stifel, Wells Fargo Securities and BTIG are also acting as book-running managers for the offering.

A registration statement on Form S-1 related to these securities has been filed with the U.S. Securities and Exchange Commission and has become effective. The offering is being made only by means of a prospectus. Copies of the prospectus, when available, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, by telephone at (800) 747-3924, or by email at prospectus@psc.com; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.

Investor Contact
ir@billiontoone.com

Media Contact
billiontoone@moxiegrouppr.com

FAQ

What price did BillionToOne (BLLN) set for its IPO on November 6, 2025?

The IPO was priced at $60.00 per share for 4,551,100 Class A shares.

How much gross proceeds will BillionToOne (BLLN) raise from the IPO?

The offering is expected to generate approximately $273.1 million in gross proceeds before fees.

When will BillionToOne (BLLN) start trading on Nasdaq and under what ticker?

Shares are expected to begin trading on the Nasdaq Global Select Market on November 6, 2025 under the ticker BLLN.

When is the BillionToOne (BLLN) offering expected to close?

The offering is expected to close on November 7, 2025, subject to customary closing conditions.

What is the underwriters' option for BillionToOne (BLLN) IPO?

Underwriters have a 30-day option to purchase up to 682,665 additional shares at the IPO price, less discounts and commissions.

Where can investors obtain the BillionToOne (BLLN) prospectus for the IPO?

Prospectus copies will be available from the listed book-runners, including J.P. Morgan, Piper Sandler, Jefferies, and William Blair.